Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.

@article{Shikiar2007AdalimumabTI,
  title={Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.},
  author={Richard Shikiar and Michael W. Heffernan and Richard G. B. Langley and Mary Kaye Willian and Rebecca S. Hoffman and Dennis A. Revicki},
  journal={The Journal of dermatological treatment},
  year={2007},
  volume={18 1},
  pages={
          25-31
        }
}
BACKGROUND Psoriasis substantially impairs the health-related quality of life (HRQOL) of patients, and a comprehensive evaluation of treatment includes HRQOL measures. OBJECTIVE To assess the impact of adalimumab on patient-reported outcomes (PROs) of patients with moderate to severe psoriasis. METHODS In a Phase II, randomized, controlled trial, the efficacy and safety of two dosages of adalimumab (40 mg weekly or every other week) versus placebo were assessed for 12 weeks in the treatment… CONTINUE READING
BETA

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 38 CITATIONS

Comparative Efficacy of Biologics in Psoriasis

  • American Journal of Clinical Dermatology
  • 2012
VIEW 4 EXCERPTS
HIGHLY INFLUENCED

The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial.

  • Journal of the American Academy of Dermatology
  • 2010
VIEW 4 EXCERPTS
CITES METHODS, RESULTS & BACKGROUND
HIGHLY INFLUENCED

Similar Papers

Loading similar papers…